Imaging of Solid Tumors Using 18F-TRX
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany nowotwór stały z przerzutami
- •Zdolność do zrozumienia istoty badania i podpisania zgody
- •Dobry stan ogólny (ocena 0 lub 1 w skali ECOG)
- •Ujemny test ciążowy (u kobiet w wieku rozrodczym)
- •Prawidłowe wyniki badań krwi (liczba białych krwinek, płytek krwi, hemoglobina)
- •Prawidłowe funkcje wątroby (niskie wartości билирубины i enzymów)
- •Prawidłowa funkcja nerek (klirens kreatyniny powyżej 50 ml/min)
✗ Disqualifies
- •Stany lub okoliczności, które mogą utrudniać uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of California, San Francisco
San Francisco, United States
Trial contact
Maya Aslam
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.